ANG1005

DRUG6 trials

Conditions

Advanced Solid Tumors With and Without Brain MetastasesAnaplastic AstrocytomaAnaplastic OligodendrogliomaBrain MetastasesBrain Tumor, RecurrentBreast CancerBreast Cancer With Recurrent Brain MetastasesGlioblastoma

Phase 1

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

CompletedNCT00539383

Angiochem IncAdvanced Solid Tumors With and Without Brain Metastases

Start: 2007-10-31End: 2010-03-31Updated: 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

CompletedNCT00539344

Angiochem IncRecurrent or Progressive Malignant Glioma

Start: 2007-10-31End: 2010-03-31Updated: 2014-07-31

Phase 2

ANG1005 in Patients With Recurrent High-Grade Glioma

CompletedNCT01967810

Angiochem IncBrain Tumor, Recurrent, Glioblastoma, Glioma

Start: 2013-10-31End: 2017-09-30Updated: 2020-02-25

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

CompletedNCT02048059

Angiochem IncBrain Metastases, Breast Cancer

Start: 2014-04-30End: 2017-09-30Updated: 2020-02-25

Phase 3

ANG1005 in Leptomeningeal Disease From Breast Cancer

NCT03613181

Angiochem IncBrain Metastases, HER2-negative Breast Cancer, Leptomeningeal Carcinomatosis +1

Start: 2023-12-31End: 2024-12-31Target: 150Updated: 2023-04-24

Unknown Phase

Expanded Access to ANG1005 for Individual Patients

NCT02755987

Angiochem IncAnaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases +1

Updated: 2016-06-07

Neuro-Oncology Advances2024-01-016 citations

ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.

Journal of Clinical Oncology2016-05-2021 citations

Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors.

Journal of Clinical Oncology2014-05-205 citations